OHI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Omega Healthcare Investors Inc (OHI) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The stock's strong financial performance, hedge fund buying trends, and positive analyst sentiment outweigh the lack of immediate technical or AI trading signals. The company's growth in revenue, net income, and EPS, combined with its strategic focus on senior housing, make it a promising long-term investment.
The technical indicators present a mixed picture. The MACD is negative and expanding, suggesting bearish momentum, while the RSI is neutral at 43.968. However, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating an overall upward trend. The stock is trading near its pivot level of 47.643, with support at 46.57 and resistance at 48.716.
Hedge funds are significantly increasing their positions, with a 251.64% increase in buying over the last quarter.
Strong financial performance in Q4 2025, with revenue up 14.28% YoY, net income up 44.53% YoY, and EPS up 34.15% YoY.
Analysts have raised price targets, with some projecting up to $54, and positive sentiment around senior housing growth.
The stock has a 60% chance of gaining 3.01% in the next day and 24.04% in the next month.
The MACD is negative and expanding, indicating bearish momentum.
Some analysts have downgraded the stock, citing valuation concerns and limited upside in the near term.
The gross margin dropped slightly (-0.14% YoY), which could be a minor concern for profitability.
In Q4 2025, Omega Healthcare demonstrated strong financial growth: Revenue increased by 14.28% YoY to $319.2M, net income rose by 44.53% YoY to $163.8M, and EPS grew by 34.15% YoY to 0.55. However, the gross margin slightly declined to 98.63% (-0.14% YoY).
Analyst sentiment is mixed but leans positive. Several firms, including Cantor Fitzgerald and UBS, have raised price targets to $52 and $51, respectively, with Buy or Overweight ratings. However, Wells Fargo and BMO Capital have downgraded the stock, citing valuation concerns and limited upside. The consensus price target range is $45-$54, with a median target of $48.
